Novel double and single ryanodine receptor 1 variants in two austrian malignant hyperthermia families

Anesthesia and Analgesia

Volumn 114, Issue 5, 2012, Pages 1017-1025

  Kaufmann, Alexius ^a   Kraft, Birgit ^a   Michalek Sauberer, Andrea ^a   Weindlmayr, Marta ^a   Kress, Hans G ^a   Steinboeck, Ferdinand ^b   Weigl, Lukas G ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CAFFEINE; CALCIUM ION; CHLOROCRESOL; DANTROLENE; FENTANYL; FURA 2 ACETOXYMETHYL ESTER; HALOTHANE; PROPOFOL; RYANODINE RECEPTOR 1; SEVOFLURANE; SUXAMETHONIUM;

ADOLESCENT; ADULT; ARTICLE; AUSTRIA; CALCIUM TRANSPORT; CLINICAL ARTICLE; FEMALE; GENERAL ANESTHESIA; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MALIGNANT HYPERTENSION; MALIGNANT HYPERTHERMIA; MUSCLE BIOPSY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SKELETAL MUSCLE;

AMINO ACID SUBSTITUTION; ANESTHESIA, GENERAL; ANESTHETICS, INHALATION; CAFFEINE; CALCIUM; CELLS, CULTURED; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CYTOPLASM; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; GENETIC VARIATION; HALOTHANE; HUMANS; MALE; MALIGNANT HYPERTHERMIA; MUSCLE FIBERS, SKELETAL; MUSCLE, SKELETAL; PEDIGREE; POLYMERASE CHAIN REACTION; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; TONSILLECTOMY;

EID: 84860312573     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e31824a95ad     Document Type: Article

References (27)

1. MacLennan DH, Zvaritch E. Mechanistic models for muscle diseases and disorders originating in the sarcoplasmic reticu-lum. Biochim Biophys Acta Mol Cell Res 2011;1813:948-64
2. Rosenberg H, Davis M, James D, Pollock N, Stowell K. Malignant hyperthermia. Orphanet J Rare Dis 2007;2:21
3. Robinson R, Carpenter D, Shaw MA, Halsall J, Hopkins PM. Mutations in RYR1 in malignant hyperthermia and central core disease. Hum Mutat 2006;27:977-89 (Pubitemid 44454050)
4. Chen P-L, Chang Y-W, Chen C-Y, Hsiang Y-C, Day Y-J. Novel variants near the central domain of RYR1 in two malignant hyperthermia-susceptible families from Taiwan. Anesth Analg 2009;109:1273-7
5. Broman M, Gehrig A, Islander G, Bodelsson M, Ranklev-Twetman E, Ruffert H, Muller CR. Mutation screening of the RYR1-cDNA from peripheral B-lymphocytes in 15 Swedish malignant hyperthermia index cases. Br J Anaesth 2009;102: 642-9
6. Ørding H, Brancadero V, Cozzolino S, Ellis FR, Glauber V, Gonano EF, Halsall PJ, Hartung E, Heffron JJA, Heytens L, Kozak-Ribbens G, Kress HG, Krtvosic-Horber R, Lehman-Horn F, Mortier W, Nivoche Y, Ranklev-Twetman E, Sigurd-son S, Snoeck M, Stieglitz P, Tegazzin V, Urwyler A, Wappler F. In vitro contracture test for the diagnosis of malignant hyperthermia following the protocol of the European MH group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. Acta Anaesthesiol Scand 1997;41: 955-66 (Pubitemid 27414735)
7. Brinkmeier H, Mutz JV, Seewald MJ, Melzner I, Rudel R. Specific modifications of the membrane fatty acid composition of human myotubes and their effects on the muscular sodium channels. Biochim Biophys Acta 1993;1145:8-14 (Pubitemid 23026347)
8. McCarthy TV. Mutation screening of the ryanodine receptor gene in malignant hyperthermia. In: Schulte an Esch J, Scholz J, Wappler F, eds. Malignant Hyperthermia. Lengerich, Germany: Pabst Science, 2000:200-11
9. Monnier N, Procaccio V, Stieglitz P, Lunardi J. Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet 1997;60:1316-25 (Pubitemid 27258063)
10. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985;260:3440-50 (Pubitemid 15114340)
11. Thomas A, Delaville F. The use of fluorescent indicators for measurements of cytosolic free calcium concentration in cell populations and single cells. In: McCormack J, Cobbold P, eds. Cellular Calcium: A Practical Approach. New York: Oxford University Press, 1991:1-54
12. Kaufmann A, Kraft B, Michalek-Sauberer A, Weigl LG. Novel ryanodine receptor mutation that may cause malignant hyperthermia. Anesthesiology 2008;109:457-64
13. Manning BM, Quane KA, Lynch PJ, Urwyler A, Tegazzin V, Krivosic-Horber R, Censier K, Comi G, Adnet P, Wolz W, Lunardi J, Muller CR, McCarthy TV. Novel mutations at a CpG dinucleotide in the ryanodine receptor in malignant hyperthermia. Hum Mutat 1998;11:45-50 (Pubitemid 128679148)
14. Sambuughin N, Holley H, Muldoon S, Brandom BW, de Bantel AM, Tobin JR, Nelson TE, Goldfarb LG. Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the North American population. Anesthesiology 2005;102:515-21 (Pubitemid 40315139)
15. Gillard EF, Otsu K, Fujii J, Khanna VK, de Leon S, Derdemezi J, Britt BA, Duff CL, Worton RG, MacLennan DH. A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia. Genomics 1991;11:751-5
16. Otsu K, Khanna VK, Archibald AL, MacLennan DH. Cosegre-gation of porcine malignant hyperthermia and a probable causal mutation in the skeletal muscle ryanodine receptor gene in backcross families. Genomics 1991;11:744-50
17. Quane KA, Ording H, Keating KE, Manning BM, Heine R, Bendixen D, Berg K, Krivosic-Horber R, Lehmann-Horn F, Fagerlund T, McCarthy TV. Detection of a novel mutation at amino acid position 614 in the ryanodine receptor in malignant hyperthermia. Br J Anaesth 1997;79:332-7 (Pubitemid 27404047)
18. Paul-Pletzer K, Yamamoto T, Bhat MB, Ma J, Ikemoto N, Jimenez LS, Morimoto H, Williams PG, Parness J. Identification of a dantrolene-binding sequence on the skeletal muscle ryanodine receptor. J Biol Chem 2002;277:34918-23
19. 2+ channel regulation. J Biol Chem 2000;275:11618-25 (Pubitemid 30237720)
20. Manning BM, Quane KA, Ording H, Urwyler A, Tegazzin V, Lehane M, O'Halloran J, Hartung E, Giblin LM, Lynch PJ, Vaughan P, Censier K, Bendixen D, Comi G, Heytens L, Monsieurs K, Fagerlund T, Wolz W, Heffron JJ, Muller CR, McCarthy TV. Identification of novel mutations in the ryanodine-receptor gene (RYR1) in malignant hyperthermia: genotype-phenotype correlation. Am J Hum Genet 1998;62: 599-609 (Pubitemid 28164617)
21. Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. J Mol Biol 1982;157:105-32
22. Weigl LG, Ludwig-Papst C, Kress HG. 4-chloro-m-cresol cannot detect malignant hyperthermia equivocal cells in an alternative minimally invasive diagnostic test of malignant hyperthermia susceptibility. Anesth Analg 2004;99:103-7 (Pubitemid 38808173)
23. Gilly H, Musat I, Fricker R, Bittner RE, Steinbereithner K, Kress HG. Classification of malignant hyperthermia-equivocal patients by 4-chloro-M-cresol. Anesth Analg 1997;85:149-54 (Pubitemid 27342292)
24. Fessenden JD, Feng W, Pessah IN, Allen PD. Amino acid residues gln4020 and lys4021 of the ryanodine receptor type 1 are required for activation by 4-chloro-m-cresol. J Biol Chem 2006;281:21022-31 (Pubitemid 44115443)
25. Metterlein T, Schuster F, Kranke P, Roewer N, Anetseder M. In-vitro contracture testing for susceptibility to malignant hyperthermia: can halothane be replaced? Eur J Anaesthesiol 2011;28:251-5
26. Hopkins PM. Malignant hyperthermia: pharmacology of triggering. Br J Anaesth 2011;107:48-56
27. Urwyler A, Deufel T, McCarthy T, West S. Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. Br J Anaesth 2001;86:283-7 (Pubitemid 32103424)